Literature DB >> 24125682

[Relationship between chemokine axis CXCL12-CXCR4 and epithelial ovarian cancer].

Qing Guo1, Xiao-hua Wu, Ying-pu Lü, Bo Yang, Feng Xu, Shao-jing Zhang.   

Abstract

OBJECTIVE: To explore the relationship between chemokine axis CXCL12-CXCR4 and the pathogenesis and severity of epithelial ovarian cancer.
METHODS: SKOV3 transfected with plasmid, SKOV3 transfected with vector and SKOV3 were cultured in vitro. Methyl thiazolyl tetrazolium (MTT) was used to analyze the effects of different concentrations of CXCL12 on the proliferation, migration and invasion of three cell lines and examine the inhibition of neutralizing CXCR4 antibody or antagonist AMD3100. And the load and weight of acquired tumor were determined at different concentrations of CXCL12.
RESULTS: CXCL12 could promote the proliferation, migration and invasion of SKOV3/CXCR4 cells in a dose-dependent fashion (P < 0.05). The effect on CXCL12 tumorigenesis could be inhibited by neutralizing CXCR4 antibody or antagonist AMD3100 (P < 0.05). Significant differences existed in the mean survival time, load and weight of metastatic tumors among the three nude mice.
CONCLUSION: A close correlation exists between chemokine axis CXCL12-CXCR4 and the pathogenesis, metastasis of epithelial ovarian cancer. The above axis may be an important pathogenic factor of epithelial ovarian cancer. And the antibody of CXCL12-CXCR4 is probably effective in its management.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24125682

Source DB:  PubMed          Journal:  Zhonghua Yi Xue Za Zhi        ISSN: 0376-2491


  2 in total

Review 1.  CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks.

Authors:  F Guo; Y Wang; J Liu; S C Mok; F Xue; W Zhang
Journal:  Oncogene       Date:  2015-05-11       Impact factor: 9.867

Review 2.  Advances in Research on the Effects and Mechanisms of Chemokines and Their Receptors in Cancer.

Authors:  Jing Xu; Jing-Quan Li; Qi-Lei Chen; Elena A Shestakova; Vsevolod A Misyurin; Vadim S Pokrovsky; Elena M Tchevkina; Hu-Biao Chen; Hang Song; Jian-Ye Zhang
Journal:  Front Pharmacol       Date:  2022-06-13       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.